Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes

Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with cognitive dysfunction, memory decline, and behavioral disturbance, and it is pathologically characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. Although various hypotheses have been p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Hisayuki Katsuyama
Format:	Article
Language:	English
Published:	MDPI AG 2024-12-01
Series:	Molecules
Subjects:	Alzheimer’s disease amyloid beta glucagon-like peptide 1 receptor agonists insulin resistance oxidative stress type 2 diabetes
Online Access:	https://www.mdpi.com/1420-3049/29/24/5936
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes
by: Qiumei Zhang, et al.
Published: (2025-05-01)

Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease
by: Melinda Urkon, et al.
Published: (2025-04-01)

GLP-1R as a potential link between diabetes and Alzheimer’s disease
by: Shujun Li, et al.
Published: (2025-07-01)

Semaglutide and the Retina
by: Zachary T. Bloomgarden
Published: (2025-04-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
by: Cheney C, et al.
Published: (2025-05-01)

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatment
by: Se-Eun Kim, et al.
Published: (2025-05-01)

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide
by: Laura Patton, et al.
Published: (2025-07-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Characterization of treatment intensified (add‐on to metformin) adults with type 2 diabetes in Thailand: A cross‐sectional real‐world study (CONVERGE)
by: Chutintorn Sriphrapradang, et al.
Published: (2025-06-01)

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
by: Olga P. Kovtun, et al.
Published: (2025-05-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes
by: Anna A Mosikian, et al.
Published: (2022-03-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
by: Saleh Alali, et al.
Published: (2025-05-01)

Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
by: Zhixuan Xie, et al.
Published: (2025-07-01)

The hidden impact of GLP‐1 receptor agonists on endometrial receptivity and implantation
by: Alberto Sola‐Leyva, et al.
Published: (2025-02-01)

Glucagon-like peptide-1 receptor agonist use is associated with reduced risk of out-of-hospital cardiac arrest in women with type 2 diabetes: A nationwide nested case-control study
by: Talip E. Eroglu, et al.
Published: (2024-12-01)

The Neuroprotective Effects of GLP-1 Analogues on Alzheimer's Disease – A Literature Review
by: Wiktoria Ulicka, et al.
Published: (2025-04-01)

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
by: Wael R. Sidrak, et al.
Published: (2024-11-01)

Research progress on the effect of type 2 diabetes and hypoglycemic drugs on the prognosis of patients with colorectal cancer
by: ZHANG Meng，LEI Xuefen，CHEN Haixia，CHEN Yixuan，JIANG Li
Published: (2025-07-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
by: Anqi Lin, et al.
Published: (2025-03-01)

Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis
by: Xiaoyu Ren, et al.
Published: (2025-07-01)

The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
by: Areesha Moiz, et al.
Published: (2025-08-01)

Semaglutide in people with obesity and type 2 diabetes on hemodialysis: a prospective analysis of glycemic and weight outcomes
by: Akinori Hayashi, et al.
Published: (2025-05-01)

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
by: Yiwen Liu, et al.
Published: (2025-05-01)

Investigation of potential relationship between glucagon-like peptide 1 receptor agonists with suicide/self-injury: disproportionality analysis using WHO-VigiBase
by: Ye Young Kim, et al.
Published: (2024-12-01)

Comparison of Effects of Glucagon-Like Peptide-1 Receptor Agonists Compared to Long-Acting Insulin, Added to Oral Anti-Diabetic Agents on Self-Management Behaviors, Anxiety, and Sleep Quality in Patients with Type 2 Diabetes
by: Song X, et al.
Published: (2025-03-01)

Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
by: Yan H, et al.
Published: (2024-11-01)

Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
by: Yosra Turkistani
Published: (2025-04-01)

Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
by: A. G. Barajas, et al.
Published: (2025-05-01)

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
by: Sho Furusawa, et al.
Published: (2024-06-01)

Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials
by: Obieda Altobaishat, et al.
Published: (2025-12-01)